Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats

Atherosclerosis. 1988 Oct;73(2-3):191-5. doi: 10.1016/0021-9150(88)90041-x.

Abstract

The effect of CS-514 (pravastatin; Sankyo Co., Tokyo), a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, on triglyceride turnover, was studied in male Wistar rats. CS-514 (15 +/- 1 mg/day per rat) was administered as a 0.04% solution in drinking water for 14 days. Triglyceride and cholesterol in very low density lipoprotein (VLDL) and plasma triglyceride were reduced by treatment with CS-514. Plasma cholesterol level was not suppressed by CS-514. The CS-514 treated rats had a significantly suppressed triglyceride secretion rate (TgSR) during the fed state compared to control rats (0.85 +/- 0.1 vs. 1.07 +/- 0.3 mg/min, P less than 0.05). By contrast, CS-514 treatment did not suppress TgSR after an overnight fast. These data demonstrate that CS-514, an inhibitor of cholesterol biosynthesis can suppress VLDL-triglyceride secretion in rats and that this effect can be modified by dietary manipulation.

MeSH terms

  • Animals
  • Cholesterol / metabolism
  • Fasting
  • Heptanoic Acids / pharmacology*
  • Lipoproteins, VLDL / metabolism*
  • Male
  • Naphthalenes / pharmacology*
  • Pravastatin
  • Rats
  • Rats, Inbred Strains
  • Triglycerides / metabolism*

Substances

  • Heptanoic Acids
  • Lipoproteins, VLDL
  • Naphthalenes
  • Triglycerides
  • Cholesterol
  • Pravastatin